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Summary Trilostane and Aminoglutethimide, each given with a physiological replacement dose of hydrocor-
tisone, were randomly allocated to 72 eligible postmenopausal advanced breast cancer patients; following
treatment failure on either drug the patient continued with the other drug, if in a suitable clinical condition.
Thirty-eight patients initially received Trilostane of whom 19 subsequently received Aminoglutethimide; 34
patients initially had Aminoglutethimide and seven of these then received Trilostane. Both groups of patients
were comparable in all respects.
There was no difference in the objective response rate to either drug, Trilostane 11/38 = 29%, Aminog-
lutethemide 12/34 = 35%, nor in the average time to disease progression for the two drugs, Trilostane 64
weeks, Aminoglutethemide 68 weeks. Of the 26 patients who received both drugs, four showed a response to
both suggesting no cross resistance. Side effects were seen to both drugs in approximately half of the patients,
but were mainly gastro-intestinal with Trilostane and rash and drowsiness with Aminoglutethimide. There was
no evidence of cross over patient susceptibility to side effects.
Aminoglutethimide is a widely used second line agent for the
treatment of advanced postmenopausal breast cancer. It is
considered to act primarily by inhibiting the aromatase
enzyme but also has some inhibitory activity on desmolase. It
is administered with a physiological replacement dose of
glucocorticoid to prevent reflex hypothalamic/pituitary
activation of the adrenal cortex following reduction in the
excretion of adrenal corticoids, but also prevents the increase
in androgens which occurs when Aminoglutethimide is given
alone. Trilostane[(4 5 17)4,5-epoxy-3,17 dihydroxyandrost-2-
ene-2-carbonitrile.] is a synthetic steroid which specifically
inhibits the 3 beta-hydroxysteroid dehydrogenase, A 5:4
isomerase enzyme system and this drug will also reduce
adrenal steroid output, when given concurrently with a
glucocorticoid to prevent reflex ACTH stimulation. Since
both drugs thus affect adrenal corticosteroid production,
both may be expected to reduce circulating oestrogen levels;
Aminogluthemide by aromatase inhibition and some effect
on the adrenal cortex, and Trilostane by a reduction in the
adrenal androgen production - the essential precursors of
oestrogen in postmenopausal women (Figure 1).
An open multicentre phase II study conducted in the UK
(Williams et al., 1987), during 1982/3, confirmed the activity
of Trilostane in postmenopausal advanced breast cancer
previously reported (Beardwell et al., 1983; Wilkinson et al.,
1984; Murray & Pitt, 1987). The study reported in this paper
was therefore designed to compare directly Trilostane with
Aminogluthemide and following failure to either agent to
administer the other drug in order to determine if the two
therapies, which both reduce circulating oestrogens, were so
similar in their pharmalogical action as to be mutually ex-
clusive.
Materials and methods
Trial design
This study was a randomised cross over multicentre com-
parative study of Trilostane vs Aminogluthemide, both given
with a physiological replacement dose of glucocorticoid.
Patients continued on the first drug until either disease pro-
gression or side effects necessitated cessation of treatment;
they then proceeded to the second drug if they continued to
fulfil the entry criteria.
Entry criteria
Eligible patients were those with inoperable, recurrent or
metastatic breast carcinoma where the initial diagnosis had
been confirmed by histology and there was objective evidence
of disease progression as defined by the International Union
against Cancer (Heyward et al., 1977) and in whom the
disease was measurable or evaluable by imaging techniques.
Only patients, who in addition, fulfilled the following entry
criteria were eligible;
- Postmenopausal, defined as at least 1 year since the last
menstrual period, 6 months after oophorectomy with
resultant amenorrhoea, or aged more than 50 years if
previous hysterectomy without oophorectomy.
- With a life expectancy of more than 3 months.
- Mobility not restricted by disease.
- No CNS involvement and no massive liver or pulmonary
involvement and essentially normal or stable cardiac, pul-
monary, hepatic, renal, endocrine and haemopoetic status.
- No previous or current malignancy of other tissues (excep-
ting adequately treated in situ carcinoma of the cervix, or
basal/squamous skin carcinoma).
- Have resolved any toxic manifestations of localised
radiotherapy.
- Have received previous hormone therapy, but only
adjuvant chemotherapy.
Patients whose sole manifestation of disease was hilar
enlargement, pleural effusion, ascites, lymphoedema, CNS
involvement, marrow suppression or osteoblastic lesions were
not eligible.
Dosage
Trilostane was supplied in capsules each containing 120 mg
by Sterling Winthrop Ltd; Aminoglutethimide and Hydrocor-
tisone were normal commerical preparations.
All drugs were administered orally and from day 1 all
patients received 20 mg Hydrocortisone daily in divided
doses.
Aminoglutethimide was administered
Day 1-14 250mg b.d.
Day 15 onwards 250mg q.i.d. or the maximum
tolerated dose
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Figure 1 Diagram of steroid biosynthesis showing location of Aminoglutethimide (AG) and Trilostane blocks.
Trilostane was administered
Day 1-3 120mg b.d.
Day 4-6 120mg q.i.d.
Day 7-9 240mg t.i.d.
Day 10 onwards 240 mg q.i.d. or the maximum
tolerated dose
Assessments
At the start of each drug therapy, at 6 and 12 weeks, and
thereafter at 12 week intervals, or as appropriate, clinical
assessments including history, physical examination, and ap-
propriate radiological, isotopic, biochemical and
haematological screens, were performed. In addition all
adverse events were recorded but direct questions were
avoided.
Response criteria
The criteria used to record response were as defined by the
UICC (5); these essentially are:
Complete response (CR) - disappearance of all known
disease with calcification of any lytic bone lesions.
Partial response (PR) - minimum of 50% decrease in
measurable lesions and objective improvement in evaluable
but non-measurable lesions with no lesions showing pro-
gression.
No change (NC) - measurable lesions decrease less than 50%
or increase less than 25%. If non-measurable but evaluable
lesions represent the majority of disease and do not res-
pond but measurable do, this is still classified as NC.
Disease progression (PD) - any measurable lesions increasing
more than 25% and/or appearance of any new lesions.
The duration of response was measured from day 1 of
treatment until disease progression; if patients continued on
therapy after evidence of progression this was recorded
separately.
Response recording
Although patients' responses were recorded according to
UICC criteria they were further grouped as follows:
Responders (R) - CR and PR plus NC for a minimum of 26
weeks (Lawrence et al., 1980).
Non responders (NR) - progressive disease appearing at
more than 6 weeks and less than 26 weeks.
Inadequate Treatment Length (IT) - patients stopping for
progressive disease at 6 weeks or less (ITPD) and for any
other cause before 12 weeks (e.g. death (IDT), side effects
(ITSE), change of address etc. (ITO).
Receptor status when known was listed as such but where
unknown was assumed to be positive if there was a history of
an objective response to hormone therapy lasting at least 12
weeks or an unknown response lasting 26 weeks or more.
When evaluating previous hormone exposure an oophrec-
tomy within the preceding 10 years was counted as one
course unless a valid alternative reason to breast cancer was
stated.
Results
A total of 75 patients entered the study in five hospitals and
of these 72 were available for analysis. Thirty-eight patients
received Trilostane first of whom 19 crossed to Aminoglute-1212 C.J. WILLIAMS et al.
thimide. Thirty-four patients received Aminoglutethimide
first but only seven crossed to Trilostane. The patients in the
two arms were similar in all respects and are listed in Tables
I and IA under the drug first received and according to their
response to it. It is apparent that there are no major differ-
ences between the patients in the two arms nor in the charac-
teristics of the patients with the different responses.
The overall response of the patients to the two drugs is
similar and is listed in Table II. If there is a true 6%
difference between the objective response rate of the two
drugs, 950 patients would be required in each group to show
a difference (5% level with 80% power), and, if the larger
difference in response rate seen when stable disease is
included is correct, then 76 patients per group would still be
required. Whilst there are no significant differences between
the response rate or the time to disease progression of the
two drugs, the proportion of patients crossing to the second
drug is different - for Trilostane to Aminoglutethmide it is
19/38 = 50% and for Aminoglutethimide to Trilostane it is
7/34 = 21% (Test for unpaired proportions z = 2.6, P is
<0.01). This difference is due to the proportion of patients
on Aminoglutethimide who were not transferred to Trilos-
tane because of their advanced disease state (11/34 = 32%)
compared with the proportion of similarly ill patients who
were not transferred from Trilostane to Aminoglutethemide
(2/38=5%; ibid test z=2.97 P=<0.01).
If the patients who received both drugs are considered
separately according to their response to both drugs then
Table III results, which shows that nine patients had a
similar result to both drugs and of the remaining 17, eight
responded to Aminoglutethimide (five of whom had a IT to
Trilostane) and five responded to Trilostane (two of whom
Table I Patients details
Characteristics Trilostane 1st therapy Aminoglutethimide Ist therapy
Type ofresponse with R NR IT R NR IT
no. ofpatients CR 1 CR 0
PR 10 PR 12
NCR 3 NCR 8
Patient total 14 12 12 20 9 5
No ofprevious hormone courses
0
1 13 12 10 17 9 4
2 1 - 2 3 1
3 or more - -
Average no. ofprevious hormone 1.07 1.00 1.17 1.2 1.0 1.2
courses
Chemotherapy history
Nil CT 13 11 12 19 6 5
Had CT 1 1 - 1 3 -
Average no. ofprevious 0.07 0.08 0 0.05 0.33 0
CT courses
Receptor status
Known E +ve - 1 - 1 1 -
Assumed E + ve 13 10 8 17 7 2
Known E -ve
Assumed E - ve 1 1 4 2 1 3
Table IA Patients details continued
Characteristics Trilostane 1st therapy Aminoglutethimide 1st therapy
Type ofresponse R NR IT R NR IT
Site oftumour
Bone 1 5 2 7 2 1
Soft tissue 8 2 3 6 2 2
Bone and soft tissue 2 2 3 3 5 1
Lung involved 3 2 3 4 - I
Liver involved - 1 1 - - -
No. ofdifferent tissues involved
1 9 7 6 13 4 3
2 4 3 5 4 5 1
3 or more 1 2 1 3 - 1
Average no. oftissues involved 1.43 1.58 1.58 1.50 1.56 1.60
Average age 69.4 65.8 61.4 63.9 66.1 68.6
(STD) (6.96) (7.85) (12.62) (9.21) (8.06) (6.05)
Average age (STD) 65.7 (9.93) 65.2 (8.69)
Years since menopause
less than - - - - - -
I toS - 1 3 3 1 -
6to 10 3 4 4 8 2 -
more than 10 10 7 2 6 4 5
Unknown 1 - 3 3 2 -
Type ofmenopause
Normal 13 12 9 16 8 5
Artificial - - 3 4
Hysterectomy only or unknown 1 - - - 1AMINOGLUTETHIMIDE AND TRILOSTANE FOR BREAST CANCER 1213
Table II Patients responses
Trilostane lst.38 crossed to Aminoglutethimide 19
Aminoglutethimide Ist.34 crossed to Trilostane 7
Trilostane Ist & 2nd Therapy Amino'mide 1st & 2nd Therapy
No. ofpatients 38 (100%) 7 (100%) 34(100%) 19 (100%)
Withdrawn before 12/52 for:
side effects ITSE 4 1 2 2
death ITD 1 - 2
other causes ITO 1 - -1
Withdrawn at or before 6/52 for
disease progression ITPD 6 3 1 1
Total ITs 12 (32%) 4 (57%) 5 (15%) 4 (21%)
No. of responders CR 1 -
PR 10 12 7
NC 26/52 or more 3 1 8 2
Total responders 14 (37%) 1 (14%) 20 (59%) 9 (47%)
No. of non-responders
NC less than 26/52 7 1 1 3
PD12tol5/52 4 1 4 2
ITPD 7 to 11/52 1 - 4 1
Total non-responders 12 (31%) 2 (29%) 9 (26%) 6 (32%)
Percentage responders of evaluable
patients* 54 33 69 60
Average time to disease progression for
responders 63.9 wks 40 wks 67.9 wks 41.2 wks
(STD) (46.60) (37.77) (17.19)
Ist and 2nd Combined Ist and 2nd Combined
Percentage responders of evaluable
patients* 52 66
Average time to disease progression for
responders 62.3 wks 59.6 wks
(STD) (45.44) (34.85)
*The proportion of Responders on first treatment and combined first and second treatments for Trilostane is not
significantly different from the proportion ofResponders to Aminoglutethimide in the respective group (Test for unpaired
proportions P is >0.2).
Table III Patients' responses who received both therapies
Aminoglutethimide
R NR IT
u R 4 3 2
o NR 3 4 1
I.T
IT 5 3 1
had an IT to Aminoglutethimide). The drugs do not there-
fore show any difference (McNemar Test P approximately
0.2). However it is also apparent that four of the 26 patients
(15%) responded to both therapies whilst a further 13 (50%)
responded to one therapy and not the other.
No drug related abnormalities were seen in any of the
biochemical or haematological screens conducted during the
study.
Side effects
The side effects reported in numbers and type are set out in
Table IV. They were classified according to whether thought
due to Trilostane/Aminoglutethimide or thought due to
Hydrocortisone. The total number of patients experiencing
side effects attributed to Trilostane/Aminoglutethimide is not
different between the two drugs, nor in the number of
patients experiencing side effects attributed to Hydrocor-
tisone. However the type of side effects is different; Trilostane
is primarily associated with gastro-intestinal disturbances and
Aminoglutethimide with rash and drowsiness.
Table V lists side effects associated with stopping therapy
and the same pattern is apparent, although sometimes the GI
upset reported with Trilostane was associated with full doses
of non-steroidal anti-inflammatory drugs.
Discussion
Trilostane when given with a physiological replacement dose
of Hydrocortisone inhibits the formation of adrenal steroids,
including androstenedione and testosterone the precursors of
oestrone and oestradiol respectively. Since this is the royal
route to the formation of oestrogens in postmenopausal
women, circulating oestrogens are reduced (Beardwell et al.,
1985; Tueni et al., 1987). Aminoglutethimide also produces
decreased levels ofcirculating oestrogens but this is due to its
inhibitory action on the aromatase enzyme (Santen & Mis-
bin, 1981). Aminoglutethimide in high doses also has adrenal
steroid synthesis inhibitory activity and in this respect the
two drugs are alike but Aminoglutethimide and Trilostane
block different steroid synthetic enzymes. This therefore
posed the question as to whether Trilostane and Aminoglute-
thimide conferred cross resistance to each other when used to
treat postmenopausal advanced breast cancer. Theoretically
the biochemical/pharmacological action of the drugs is
similar but it has been shown that Aminoglutethimide when
given to postmenopausal women receiving 40 mg of Hydro-
cortisone daily can cause lowering of oestrogen concentra-
tions with maintained concentration of the androgen precur-
sors (Santen & Misbin, 1981; Vermeulen, 1983). This would
then suggest that the major site of Aminoglutethimide
activity is aromatase inhibition with less effect on adrenal
steroid synthesis, as previously reported (Santen, 1982) - this
would be confirmed if no cross resistance could be shown
between the two drugs demonstrating that they act at differ-
ent sites, even when Aminoglutethimide is given in high doses
to exhibit any adrenal effect.1214 C.J. WILLIAMS et al.
Table IV Side effects. Total exposures (Combined 1st and 2nd. treatments)
Trilostane + HC
No. of patients available for analysis
No. of patients with side effects to drug
No. of patients with side effects to steroid
Total No. of patients with side effects
No. of patients stopping treatment due to side effects
No. of patients experiencing the following side effects:
Oral (burning in mouth, paraesthesia, palatal swelling,
taste disorder, lachrymation, rhinitis)*
Upper gastrointestinal (nausea, vomiting, gastritis,
heartburn, gastralgia, pyrosis)*
Lower gastrointestinal (diarrhoea, constipation,
Abdominal cramp or fullness)*
Low mineralocorticoid (dizzy on standing, listless,
postural hypotension, weakness, tired, asthenia)
Others
Rash, pruritus*
Flush, sweating
Muscle cramps (not abdominal)
Haematemesis
Headache
Drowsy, sleepy*
Pulmonary embolus
Increasing shakiness
Steroid side effects
Oedema
Hypertension
Gastric acidity (pain)
45 (100%)
22 (49%)
2
23 (51%)
8 (18%)
Aminoglutethimide
+ HC
52 (100%)**
34 (65%)
2
35 (67%)
6 (12%)
6
16
12 (D = 11)
2 (PH = 0)
2
5
1 (D=1)
5 (PH = 2)
14
17
1
*Theproportion ofpatientsexperiencing these sideeffects issignificantly different between the
two drugs (Test for unpaired proportions, Pis <0.01). **No sideeffect record available for one
patient. Code D = diarrhoea; PH = postural hypotension.
Table V Details of side effects stopping therapy
Week ofIst/2nd treatment
(TR) when stopped
Trilostane + HC
0 (1st TR)
2 (1st TR)
3 (1st TR)
3 (1st TR)
4 (2nd TR)
12 (1st TR)
12 (1st TR)
12 (1st TR)
Aminoglutethimide + HC
2 (2nd TR)
4 (2nd TR)
5 (1st TR)
10 (1st TR)
19 (1st TR)
51 (2nd TR)
Description ofside effect
Burning, swelling in mouth abdominal
pain and diarrhoea
Vomiting
Nausea epigastric pain
Fullness in face epigastric discomfort
Nausea vomiting
Dyspepsia. diarrhoea
Unwell, feeling bloated
Diarrhoea, sickness
Severe rash
Drowsy, vague, unsteady
Drowsy, tired
Rash with oedema
Extreme lethargy
Rash
Comments
One day treatment only
Stopped Trilostane and rechallenged
Mild but patient stopped
Ended when treatment stopped
Taking Ibuprofen, Diconal, M.S.T.
Taking Ibuprofen. When stopped then
onset ofdiarrhoea
Trilostane reduced but persisted ? steroid
Continuous for 2 weeks
Lasted until Aminoglutethimide stopped
Better when Aminoglutethimide stopped
Cleared when Aminoglutethimide with-
drawn
This question can only be answered with a trial using a
cross over design, which is difficult to conduct in patients
who are suffering advanced breast cancer, since following
failure to one drug they may not be in a suitable condition to
receive the second drug or it may not be ethical to delay
chemotherapy by administering another hormone. For these
reasons only 26 of the 72 patients received a second therapy.
The marked bias in a significantly (P=<0.01) greater pro-
portion of patients crossing from Trilostane to Aminoglute-
thimide than from Aminoglutethimide to Trilostane is
probably due to clinicians tending to continue with Amino-
glutethimide, even when there was evidence of disease pro-
gression. This resulted in more patients who did not fulfill
the eligibility criteria for second drug treatment with Trilos-
tane and may reflect clinicians' lesser familiarity with Trilos-
tane and possibly a belief that the two drugs acted similarly
and there was no likelihood of gain to the patient by trans-
fer.
This study strongly suggests that there is no cross resis-
tance between the two drugs since some 15% of all patients
who received both drugs responded to both. The response
rate of patients to both drugs was essentially the same;
objective response rates were 29% for Trilostane and 35%
for Aminoglutethimide (95% confidence limits 15-43% and
19-51% respectively), similarly objective response rates in-
cluding patients with no change for 6/12 or more, are Trilos-
tane 37%, Aminoglutethimide 59% (95% confidence limits
22- 52% and 42-76% respectively). No evidence of treat-
ment order effect could be discerned.
The number of patients experiencing side effects tended
(P = 0.1), to be less with Trilostane than with Aminoglute-
thimide but a high dose of Aminoglutethimide was given.AMINOGLUTETHIMIDE AND TRILOSTANE FOR BREAST CANCER 1215
There was no difference in side effect incidence attributed to
steroid between the two drugs but the pattern of side effects
attributed to each drug was markedly different. It is interest-
ing though that some of the Trilostane upper GI side effects
were associated with the concurrent administration of full
doses of non-steroidal anti-inflammatory drugs, which prob-
ably compounds the gastric irritation; but when the NSAID
was withdrawn although the gastric upset improved diar-
rhoea sometimes developed - suggesting that the diarrhoea
associated with Trilostane is prostaglandin mediated and may
be due to Trilostane inhibiting prostaglandin dehydrogenase
(Sterling Winthrop). There is no evidence that patients who
display adverse reactions to one drug will necessarily experi-
ence adverse effects on the other.
This trial then clearly demonstrates that the theoretical
pharmacological difference between Aminoglutethimide and
Trilostane is confirmed in clinical practice and that the two
drugs are true alternatives in both clinical efficacy and
patients' susceptibility. In view of this it would be interesting
to determine how reduced doses of Aminoglutethimide and
Trilostane in combination, to minimise side effects and max-
imise reduction of circulating oestrogens, would perform.
This study was supported by Sterling Winthrop Group Ltd.
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